GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remed Co Ltd (XKRX:302550) » Definitions » EBIT

Remed Co (XKRX:302550) EBIT : ₩-1,302 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Remed Co EBIT?

Remed Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ₩96 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-1,302 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Remed Co's annualized ROC % for the quarter that ended in Mar. 2024 was -1.41%. Remed Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.11%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Remed Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1.13%.


Remed Co EBIT Historical Data

The historical data trend for Remed Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remed Co EBIT Chart

Remed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 4,736.02 -1,863.14 1,658.59 5,526.75 2,223.73

Remed Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 612.82 -867.59 -1,092.60 562.53 96.07

Competitive Comparison of Remed Co's EBIT

For the Medical Devices subindustry, Remed Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Remed Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Remed Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Remed Co's EV-to-EBIT falls into.



Remed Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-1,302 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Remed Co  (XKRX:302550) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Remed Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-739.868 * ( 1 - 6.82% )/( (48393.453 + 49360.247)/ 2 )
=-689.4090024/48876.85
=-1.41 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=55060.329 - 1475.695 - ( 6254.253 - max(0, 16678.237 - 21869.418+6254.253))
=48393.453

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=61594.838 - 1885.166 - ( 11148.679 - max(0, 18645.961 - 28995.386+11148.679))
=49360.247

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Remed Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=384.268/( ( (23095.452 + max(12797.439, 0)) + (22965.912 + max(10194.771, 0)) )/ 2 )
=384.268/( ( 35892.891 + 33160.683 )/ 2 )
=384.268/34526.787
=1.11 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3844.565 + 5678.564 + 5594.256) - (1475.695 + 0 + 844.251)
=12797.439

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5113.437 + 5483.797 + 6841.933) - (1885.166 + 0 + 5359.23)
=10194.771

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Remed Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-1301.584/115359.179
=-1.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Remed Co EBIT Related Terms

Thank you for viewing the detailed overview of Remed Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Remed Co (XKRX:302550) Business Description

Traded in Other Exchanges
N/A
Address
187 Techno 2-ro, No 301-303, Gwanpyeong-dong, Yuseong-gu, Daejeon, KOR, 34025
Remed Co Ltd is a Korean medical equipment manufacturing company. The company is engaged in researching and developing products to treat brain disorders such as depression, anxiety, stroke and Parkin's. It has developed TMS device and is manufacturing pain therapy devices using advanced electromagnetic stimulation, shockwave (RSWT) and laser technologies. Its products offerings include Transcranial Magnetic simulator for brain, Electromagnetic simulators including Salus Talent, Salus Talent A, Salus Talent Pro, and Optimus Pro for pain therapy; and Rosetta, Salus RSWT and Optimus Pro as a part of Extracorporeal Shockwave Therapy. It also offers Electrosurgical units from REMED including ELPIS 4L, ELPIS 4, ELPIS 3, and ELPIS2.

Remed Co (XKRX:302550) Headlines

No Headlines